Skip to main content

Day: February 13, 2023

HomeTrust Bancshares, Inc. Announces Completion of Merger with Quantum Capital Corp.

ASHEVILLE, N.C., Feb. 13, 2023 (GLOBE NEWSWIRE) — HomeTrust Bancshares, Inc. (NASDAQ: HTBI) (“HomeTrust”), the holding company of HomeTrust Bank, today announced that its merger with Quantum Capital Corp. (“Quantum”) was completed as of February 12, 2023. The merger was a stock and cash transaction valued at approximately $70.8 million (the “Transaction”). On a pro forma basis, the combined entity will hold assets of approximately $4.3 billion, including loans of $3.6 billion and deposits of $3.6 billion. “We are pleased to announce the completion of our merger with Quantum and can now officially welcome this talented group of bankers to the HomeTrust team,” said C. Hunter Westbrook, President and Chief Executive Officer of HomeTrust. “Very early in the process we realized Quantum had a culture similar to...

Continue reading

Victoria Gold: Notice of Expiry of Offer for ATAC Resources

WHITEHORSE, Yukon, Feb. 13, 2023 (GLOBE NEWSWIRE) — Victoria Gold Corp. (TSX-VGCX) (“Victoria” or the “Company”) is providing notice that its proposed offer to ATAC Resources Ltd. (“ATAC”) will expire at the close of business on February 17, 2023. On January 12, 2023, Victoria submitted a non-binding proposal to acquire 100% of the issued share capital of ATAC. Victoria proposed to offer C$0.12 per ATAC share, payable in Victoria shares. On January 17, 2023, ATAC declined Victoria’s proposal. Following subsequent discussions between ATAC and Victoria and their respective advisors, ATAC formally confirmed its rejection of Victoria’s proposal on February 7, 2023. Victoria believes its offer is fair and generous consideration for ATAC shareholders. Victoria’s offer implies a premium of 85 percent to ATAC’s closing share price on February...

Continue reading

Astrotech Reports Second Quarter of Fiscal Year 2023 Financial Results

AUSTIN, Texas, Feb. 13, 2023 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for its second quarter of fiscal year 2023, which ended December 31, 2022. Financial Highlights & Recent Developments Astrotech’s consolidated balance sheet remains strong with $46.8 million in cash and liquid investments. Year-to-date revenue totaled $301 thousand and was generated by sales of TRACER 1000™ explosive trace detector (ETD), as well as recurring maintenance services and sales of consumables for the TRACER 1000. The decrease in revenue from the prior fiscal year is primarily the result of Astrotech shifting focus from the volatile ETD market to commercialization and marketing of the AgLAB 1000-D2. Year-to-date gross margin increased to 38% from 18%, an increase...

Continue reading

Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

First subject enrolled into the OPMD clinical development program HAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its Second Fiscal Quarter ended December 31, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended December 31, 2022 with the U.S. Securities and Exchange Commission. “In January, we were excited to announce the enrollment of the first OPMD patient into the natural history phase of the BB-301 development program, and the screening process has continued at a rapid pace. The enrollment of the first patient...

Continue reading

Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Topline trial results expected mid-March 2023 NEWTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced full enrollment of its Phase 2a proof of concept trial of ACER-801 (osanetant), a novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist, being investigated as a potential treatment option for moderate to severe Vasomotor Symptoms (VMS) associated with menopause. Topline results from this trial are expected in mid-March 2023. The Phase 2a randomized, double-blind, placebo-controlled, dose-ranging trial of ACER-801 is designed to evaluate the safety, pharmacokinetics (PK) and efficacy of ACER-801...

Continue reading

Anika Announces First Surgeries Performed Using the New RevoMotion™ Reverse Shoulder Arthroplasty System and Commences Limited Market Release in the United States

RevoMotion significantly expands Anika’s shoulder arthroplasty portfolio and provides a new solution in the over $800 million U.S. reverse shoulder market RevoMotion offers the industry’s smallest diameter threaded glenoid baseplate which preserves bone and enhances intraoperative flexibility The system’s two streamlined instrument trays are designed to drive efficiencies, reduce OR complexity, and simplify the procedure in both the hospital and ASC BEDFORD, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has commenced the limited market release of its new RevoMotion Reverse Shoulder Arthroplasty (RSA) System, with the first surgeries performed in the United States. The launch of the RevoMotion...

Continue reading

ICU Medical Announces Time of Fourth Quarter 2022 Earnings Conference Call

SAN CLEMENTE, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) —  ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2022 earnings release and conference call. The Company will release its fourth quarter 2022 results on Monday, February 27th, 2023 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Monday, February 27th, 2023. The call can be accessed at (877) 300-8521, conference ID 10174731. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company’s website at www.icumed.com, clicking on the Investors tab, clicking on the Webcast icon and following the prompts. The webcast will...

Continue reading

Bridgeline to Report Financial Results for the First Quarter of Fiscal 2023

WOBURN, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) — Bridgeline Digital, Inc. (NASDAQ: BLIN), a leading cloud-based marketing technology software provider, announced today that it will release its financial results for the first quarter of fiscal 2023 on Tuesday, February 14, 2023, at 4:30 p.m. ET. On that day, Ari Kahn, the Company’s President and Chief Executive Officer, and Thomas Windhausen, the Company’s Chief Financial Officer, plan to host a live conference call at 4:30 p.m. ET to discuss the financial results. The details and registration link for the conference call and replay are as follows:What: Bridgeline Digital First Quarter 2023 Earnings Call  When: Tuesday, February 14, 2023  Time: 4:30 p.m. ET  Registration: https://register.vevent.com/register/BI26a20973da0b419bb35d02dfa5450275  Participants...

Continue reading

SeqLL Inc. Announces Pricing of $1.8 Million Registered Direct Offering

BILLERICA, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) — SeqLL Inc. (NASDAQ: SQL and SQLLW) (“SeqLL” or the “Company”), a technology company providing life sciences instrumentation and research services, today announced that it has entered into a securities purchase agreement (the “Agreement”) with institutional investors to purchase 2,000,000 of its shares of common stock at a purchase price of $0.90 per share of common stock in a registered direct offering (the “Offering”). The gross proceeds to the Company from the Offering are estimated to be approximately $1.8 million before deducting the placement agent’s fees and other Offering expenses. Maxim Group LLC is acting as the sole placement agent in connection with the Offering. The Offering is expected to close on or about February 15, 2023, subject to the satisfaction of customary...

Continue reading

Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards

MINNEAPOLIS, Minn, Feb. 13, 2023 (GLOBE NEWSWIRE) —  Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, primarily as a result of the January 30, 2023 closing of its public offering of approximately $15 million of common stock and warrants, Panbela has regained compliance with applicable listing standards of The Nasdaq Stock Market (“Nasdaq”). Panbela Regains Nasdaq Compliance Nasdaq has issued notice that Panbela has regained compliance for continued listing of its common stock. On February 9, 2023, Panbela received a letter from Nasdaq confirming that Panbela has cured the previously identified minimum bid price and stockholders’ equity deficiencies under Nasdaq Listing Rules 5550(a)(2)...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.